Adverse events should be reported.
Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store.
Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on 01753 627777.
A link to the prescribing information can be found in the header.
Renal Cell Carcinoma
Cabozantinib Support Materials
Cabozantinib is indicated as monotherapy for advanced renal cell carcinoma:
• As first-line treatment of adult patients with intermediate or poor risk
• In adults following prior vascular endothelial growth factor (VEGF)-targeted therapy
Cabozantinib, in combination with nivolumab, is indicated for the first-line treatment of
advanced renal cell carcinoma in adults.
Background to renal cell carcinoma
Pathology of kidney cancer and renal cell carcinoma (RCC). Epidemiology of kidney cancer and RCC. Staging and prognosis of RCC. Treatment of RCC.
CBZ-UK-000200 | September 2024
Importance of cabozantinib + nivolumab for the treatment of aRCC
Hear from Prof. Laurence Albiges and Prof. James Larkin on the importance of cabo+nivo for the treatment of aRCC.
CBZ-UK-000228 | September 2024
HCP experience of using cabozantinib + nivolumab to treat patients with aRCC
Hear from Prof. Laurence Albiges and Prof. James Larkin sharing their experience of using Cabo+Nivo to treat patients with aRCC
CBZ-UK-000229 | September 2024
Supporting Patients with aRCC during treatment with cabozantinib + nivolumab
Hear from Prof. Laurence Albiges and Prof. James Larkin sharing their views on supporting patients with aRCC during treatment with cabo+nivo.
CBZ-UK-000230 | September 2024
IO/TKI Toxicity – How to work out which toxicities are coming from which drug
Toxicity Management with combination treatment – How to work out which toxicities are coming from which drug
CBZ-UK-000234 | September 2024
Cabozantinib + nivolumab 55.6-month median overall survival in 1st line advanced renal cell carcinoma
Early efficacy with sustained long-term overall survival vs sunitinib: At a median follow-up of 55.6 months (48.1 months minimum), CheckMate 9ER data for Cabozantinib + nivolumab demonstrate a 10.5-month longer mOS vs sunitinib
CBZ-UK-000280 | September 2024
Identification and management of adverse reactions with cabozantinib in patients with advanced renal cell carcinoma
A guide for healthcare professionals
CBZ-UK-000227 | September 2024
